Legend Biotech reports outcomes in CARTITUDE-4 study of CARVYKTI

Legend Biotech “announced patient-reported outcome data from the Phase 3 CARTITUDE-4 study from an oral presentation at the 2023 American Society of Hematology Annual Meeting. These data showed clinically meaningful improvement in health-related quality of life following a single CARVYKTI infusion in adults lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy, compared to patients treated with the standard of care treatment regimens of either pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone. The PRO data also demonstrated meaningful reductions in disease-specific symptoms after a single infusion for patients in the CARVYKTI(R) arm, while patients in the SOC treatment arm trended toward worsening or lower degrees of improvement from baseline for most domains and symptoms. Eligible patients in the CARTITUDE-4 study had lenalidomide-refractory MM, and had one to three prior LOT, including a proteasome inhibitor and an immunomodulatory drug. Four hundred nineteen patients were randomized, with 208 patients in the CARVYKTI(R) arm and 211 patients in the SOC arm. At the clinical cut-off on November 1, 2022, 99 patients in the CARVYKTI(R) arm and 66 patients in the SOC arm had baseline and 12-month PRO assessments, representing data prior to disease progression. When compared to SOC, patients who received the CARVYKTI(R) infusion exceeded clinically meaningful thresholds for average improvement from baseline to 12 months in global health status, pain, and the visual analogue scale.”